International Journal of Endocrinology (Jan 2023)

Correlation between the Severity of Metabolic Dysfunction-Associated Fatty Liver Disease and Serum Uric Acid to Serum Creatinine Ratio

  • Jing Liu,
  • Hongye Peng,
  • Che Wang,
  • Yutong Wang,
  • Rongrui Wang,
  • Jixiang Liu,
  • Tianhui Zhou,
  • Shukun Yao

DOI
https://doi.org/10.1155/2023/6928117
Journal volume & issue
Vol. 2023

Abstract

Read online

Purpose. As one of the most common chronic liver diseases, metabolic dysfunction-associated fatty liver disease (MAFLD) had different prognoses between mild and moderate-severe levels. Serum uric acid to serum creatinine ratio (sUA/Cr) can reflect the overall metabolic status of the body. To explore a convenient indicator to screen MAFLD and distinguish the severity of the disease, this study analyzed the correlation between sUA/Cr and the severity of MAFLD. Methods. 228 participants were enrolled and divided into 2 groups, including mild MAFLD and non-MAFLD group and moderate-severe MAFLD group, based on liver/spleen computed tomography (CT) ratios. The correlations between sUA/Cr and the severity of MAFLD were analyzed by logistic and linear regression. Receiver operating characteristics (ROCs) analyzed the predictive ability of sUA/Cr for the severity of MAFLD expressed by the area under curve (AUC). Results. The level of sUA/Cr was higher in themoderate-severe MAFLD group than mild MAFLD and non-MAFLD group (6.14 ± 1.55 vs. 5.51 ± 1.19, P=0.008). After adjustment for confounders, the correlation analysis showed that patients with elevated sUA/Cr had a higher risk of moderate-severe MAFLD (OR: 1.350, P=0.036). A higher sUA/Cr level was associated with lower liver CT values (β = −0.133, P=0.039) and liver/spleen CT ratio (β = −0.154, P=0.016). sUA/Cr had the ability to discriminate the severity of MAFLD (AUC: 0.623). Conclusion. sUA/Cr was positively associated with the risk of moderate-severe MAFLD and had the predictive ability to discriminate the moderate-severe MAFLD from mild MAFLD and non-MAFLD. The sUA/Cr level was suggested to be monitored and controlled in the screening and treatment of MAFLD.